Personal information
  • Gender:Male
  • Education Level:Graduate student graduate
  • Alma Mater:中科院上海有机所
  • Academic Titles:药学系主任
  • Degree:Doctorate
  • Status:在岗
  • School/Department:化学与材料科学学院
  • Date of Employment:2018-08-10
  • Contact Information:zhoujinming@zjnu.edu.cn
Other Contact Information
  • email:
Personal Profile

周金明 邮箱:zhoujinming@zjnu.edu.cn周金明,理学博士,研究员,博士生导师,校“双龙学者”特聘教授,药学系主任。 2006年毕业于中科院上海有机化学研究所,研究理性药物设计,获理学博士学位。2006年至2009年在加拿大麦吉尔大学(McGill University)从事抗肿瘤药物方向的博士后研究工作。2010年至2018年在北京协和医学院医药生物技术研究所工作,历任副研究员、研究员。2018年8月至今任职于浙江师范大学,主讲《药理学》、《计算机辅助的药物设计》等专业主干课程。研究方向主要聚焦基于蛋白质结构分析及基于蛋白结构的药物分子设计。目前已主持国家重点研发项目(1项),国家自然基金 (5项),重大新药创制子任务(1项),人事部回国留学人员基金(1项), 医科院院所长基金(1项),浙江省自然科学基金(1项)等,2012年入选医科院“协和新星”计划,医科院创新工程子项目负责人等,并参与973课题(1项),2014协和创新团队学术骨干。至今发表论文70余篇,其中SCI论文60余篇, 作为责任作者或第一作者的论文包含了国际药物化学主要SCI期刊如J. Med. Chem, Eur. J. Med. Chem.,Bioorg. Med. Chem. Lett.等, 其他论文包括Cell Host & Microbe, PLOS Pathogens, ACS AMI,JCTC, J. Cheminf.等。目前获得多个抗病毒、抗肿瘤先导化合物,申请及授权专利14项。研究方向:基于蛋白质靶点结构的药物分子设计,尤其是针对癌症及病毒的关键靶点,以及基于结构的先导化合物的优化,PROTACs等蛋白降解分子设计和合成等;肿瘤免疫小分子药物的开发,尤其是针对免疫检测点(Immune checkpoint)蛋白PD-1/PD-L1以及固有免疫关键蛋白STING等.重要药物分子的合成路线优化改造,医药中间体合成以及其他工艺研究。非常感谢对我们研究方向感兴趣的各位研究生及本科生并欢迎加入我们实验室团队,开启药化之旅。联系方式:zhoujinming@zjnu.edu.cn。团队公众号:科研项目:[1] 国家自然科学基金面上项目(22077115 ),新型选择性雄激素受体降解分子的发现、优化及抗前列腺癌研究。2021.1-2024.12. 主持[2] 国家自然科学基金面上项目 (81672559), 基于雷公藤单体雷酚内酯发展治疗去势抵抗前列腺癌(CRPC)的新策略. 2017.1-2020.12. 主持[3] 基于宿主限制因子等关键病原宿主相互作用的病毒传染病新型靶标发现和评价 重大新药创制子任务(2018ZX09711003-002-002)2018. 1-2020.12 主持[4] 功能分子结构分析 医科院创新工程子项目 (CAMS-I2M-1-012 ZJM),2017-2020 主持(子任务负责人)。[5]靶向活化胞内固有免疫在病毒性传染病防控中的应用 政府间国际科技创新合作/港澳台科技创新合作重点专项(2018YFE0107600) 2019. 1-2022.12 主持[6] 国家自然科学基金面上项目 (81271844), HIV-1宿主限制因子BST-2和拮抗蛋白Vpu的相互作用研究. 2013.1-2016,结题主持.[7] 国家自然科学基金交流合作项目(FRQS-NSFC合作交流, 81311120299), 利用传统中医资源寻找非小细胞肺癌的新疗法, 2013.1-2013.12, 结题主持.[8] 国家自然科学基金青年基金 (81001402), 基于雄激素受体结构的抗前列腺癌药物合理设计. 2011.1-2013.12, 结题主持.[9] 留学人员科技活动项目择优资助,靶向Vif-APOBEC3G作用面抗HIV-1先导化合物优化. 2012.1-2012.12, 结题主持.[10] 中央级公益性科研院所基本科研业务专项, 基于BST-2/Vpu/β-TrCP三分子结合模式的抗HIV-1药物研究, 2010.5-2012.5, 结题主持.[11] 北京协和医学院, 中国医学医科院“协和新星”计划, 2012年, 结题主持.[12] 2012年国家重大科学研究计划(973计划), 病毒与宿主细胞相互作用分子机制的研究(子课题), 主要学术骨干. 结题[13] 2014年度协和创新团队, 主要学术团队成员. 结题[14] 浙江省自然基金一般项目(Y21B020024),靶向宿主限制因APOBEC3G的新型抗HIV-1药物研究。2021.01-2024.12. 主持 ((LY21B020006)[15] 金华市重点项目,基于新型雄激素受体降解分子ZA22的抗前列腺癌药物研发,主持。以及多项校内主持及校企合作横向项目。 发表文章:Chenfan Li, Xiaoli Han, Qiuxia Yan, Yang Ji, Rongyu Zhang, Dazhong Yuan, Fulian Yang, Jianlong Wang#, Meng Wu#, Jinming Zhou# Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry 2024, doi: 10.1021/acs.jmedchem.3c01668. Ding J, Wang S, Liu Q, Duan Y, Cheng T, Ye Z, Cui Z, Zhang A, Liu Q, Zhang Z, Zhang N, Liu Q, An N, Zhao J, Yi D, Li Q, Wang J, Zhang Y, Ma L, Guo S, Wang J, Liang C, Zhou J*, Cen S*, Li X*. Schlafen-5 inhibits LINE-1 retrotransposition. iScience. 2023 Sep 19;26(10):107968. doi: 10.1016/j.isci.2023.107968. Zou Y, Zhang M, Zhou J*. Recent trends in STING modulators: Structures, mechanisms, and therapeutic potential. Drug Discov Today. 2023 Sep;28(9):103694. doi: 10.1016/j.drudis.2023.103694. Zhou X, Han Q, Zhou J, Liu C, Liu J. Reagentless Electrochemical Detection of Tumor Biomarker Based on Stable Confinement of Electrochemical Probe in Bipolar Silica Nanochannel Film.Nanomaterials (Basel). 2023 May 15;13(10):1645. doi: 10.3390/nano13101645. Zhou X, Ji Y, Zhou J*. Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors. Molecules. 2023 Apr 21;28(8):3615. doi: 10.3390/molecules28083615. Xie Y, Ding J, Gao J, Zhang J, Cen S, Zhou J*. Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways. Int Immunopharmacol. 2023 May;118:109993. doi: 10.1016/j.intimp.2023.109993. Bao Q, Zhou J*. Various strategies for developing APOBEC3G protectors to circumvent human immunodeficiency virus type 1. Eur J Med Chem. 2023 Mar 15;250:115188. doi: 10.1016/j.ejmech.2023.115188. Wu M, Zhang R, Zhang Z, Zhang N, Li C, Xie Y, Xia H, Huang F, Zhang R, Liu M, Li X*, Cen S*, Zhou J*. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer. Elife. 2023 Jan 19;12:e70700. doi: 10.7554/eLife.70700. Ji Y, Zhang R, Han X, Zhou J*. Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC. Eur J Med Chem. 2023 Feb 5; 247:115077. Chao Chen,#, Rongyu Zhang#, Wancheng Wei, Jinming Zhou* Anti-COVID-19 Traditional Chinese Medicine Database. Coronaviruses, 2022, 3, e281022210454. Zhu M, Shan Q, Ma L, Dong B, Wang J, Zhang G, Wang M, Zhou J*(共通讯), Cen S*, Wang Y*. Structure-based design and evaluation of benzoheterocycle derivatives as potential dual HIV-1 protease and reverse transcriptase inhibitors. Eur J Med Chem. 246:114981.. doi: 10.1016/j.ejmech.2022.114981. Ma L, Wen J, Dong B, Zhou J, Hu S, Wang J, Wang Y, Zhu M, Cen S. Design and Evaluation of Novel HIV-1 Protease Inhibitors Containing Phenols or Polyphenols as P2 Ligands with High Activity against DRV-Resistant HIV-1 Variants. Int J Mol Sci. 2022, 23(22):14178. doi: 10.3390/ijms232214178. Huang F, Han X, Xiao X*, Zhou J* Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development. Molecules. 2022, 27(22):7728. Jieke Gao, Jiantao Zhang, Xiaoli Han, Jinming Zhou* Hydrophobic tag tethering degradation, the emerging targeted protein degradation strategy. Curr Med Chem. 2023;30(27):3137-3155, doi: 10.2174/0929867329666220930120328. Shangjiu Hu, Ling Ma, Biao Dong, Qi Shan, Jinming Zhou, Guoning Zhang, Minghua Wang , Shan Cen , Mei Zhu , Juxian Wang , Yucheng Wang. A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants. Bioorg Med Chem 2022, 64:116760. Shi Q, Liao Z, Liu Z, Wen J, Li C, He J, Deng J, Cen S, Cao T, Zhou J* (通讯作者), Zhu S*. Divergent synthesis of benzazepines and bridged polycycloalkanones via dearomative rearrangement.Nat Commun. 2022 Jul 29;13(1):4402 Zhang M, Zou Y, Zhou X, Zhou J *(通讯作者). Inhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy. Front Immunol. 2022, 13: 954129. Xu Q, Zhang Z, Huang C, Bao Q, Zhang R, Wu M, Xiao X, Han X*, Li X*, Zhou J* (通讯作者). Development of novel androgen receptor antagonists based on the structure of darolutamide. Bioorg Chem. 2022, 124:105829. Cui X, Xie Y, Zhang M, Gao J, Zhou X, Ding J, Cen S*, Zhou J(通讯作者)*. Identification of Ziyuglycoside II from a Natural Products Library as a STING Agonist. ChemMedChem. 2022, 17(11): e202100719. Rongyu Zhang , Meng Wu, Tongxiang Cao, Kui Luo, Fangjiao Huang, Ruoying Zhang, Zhipeng Huang, Jinming Zhou*(通讯作者), Yongdong Wang*, Shifa Zhu* Identification of the gossypol derivatives as androgen receptor inhibitor Bioorg Med Chem Lett. 2022, 75:128952.Zhu M, Zhou H, Ma L, Dong B, Ding J, Zhou J, Wang J, Zhang G, Wang M, Shan Q, Cen S, Wang Y. Design, synthesis and biological evaluation of protease inhibitors containing morpholine cores with remarkable potency against both HIV-1 subtypes B and C. Eur J Med Chem. 2022 Apr 5;233:114251. Gao F#, Zhou J#, Sun Y, Yang C, Zhang S, Wang R*, Tan W*. Programmable Repurposing of Existing Drugs as Pharmaceutical Elements for the Construction of Aptamer-Drug Conjugates. ACS Appl Mater Interfaces. 2021 Mar 3;13(8):9457-9463. Zhu M, Shan Q, Ma L, Wen J, Dong B, Zhang G, Wang M, Wang J, Zhou J(通讯作者)*, Cen S*, Wang Y*. Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase. Eur J Med Chem. 2021 Aug 5; 220:113498. Zhu M, Zhou H, Ma L, Dong B, Zhou J, Zhang G, Wang M, Wang J, Cen S, Wang Y. Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants. Eur J Med Chem. 2021 Aug 5; 220:113450. Zhang R, Huang C, Xiao X*, Zhou J(通讯作者)*. Improving Strategies in the Development of Protein-Downregulation-Based Antiandrogens. ChemMedChem. 2021 Jul 6;16(13):2021-2033. Zhu M, Ma L, Dong B, Zhang G, Wang J, Zhou J(通讯作者)*, Cen S*, Wang Y*. Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite. Bioorg Med Chem. 2020 Aug 15;28(16):115623. Jinming Zhou(通讯作者),* and Jian Hui Wu. Binding-Site Match Maker (BSMM): A Computational Method for the Design of Multi-Target Ligands. Molecules 2020, 25, 1821. Mei Zhu, Yue Dou, Ling Ma, Biao Dong, Fan Zhang, Guoning Zhang, Juxian Wang, Jinming Zhou(通讯作者)*, Shan Cen*, and Yucheng Wang* Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants ACS Medicinal Chemistry Letters 2020 11 (6), 1196-1204. Mei Zhu, Ling Ma, Biao Dong, Guoning Zhang, Juxian Wang, Jinming Zhou(通讯作者)*, Shan Cen*,Yucheng Wang* Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1 ligands. Future Med. Chem. (2020) 12(9), 775–794. Xie Y, Ding J, Cui X, Wu M, Huang C, Zhang R, Wang J, Li X, Cen S, Zhou J(通讯作者)*. Screening of kinase inhibitors downregulating PD-L1 expression via on/in cell quantitative immunoblots. Eur J Pharm Sci. 2020 Jan 15;142:105088. Cui X, Zhou R, Huang C, Zhang R, Wang J, Zhang Y, Ding J, Li X, Zhou J(通讯作者)*, Cen S*. Identification of Theaflavin-3,3'-Digallate as a Novel Zika Virus Protease Inhibitor. Front Pharmacol. 2020 Oct 21;11:514313. Zhou H, Zhu M, Ma L, Zhou J, Dong B, Zhang G, Cen S, Wang Y, Wang J. Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study. PLoS One. 2020 Jul 22;15(7):e0235483. Zhu M, Ma L, Wen J, Dong B, Wang Y, Wang Z, Zhou J, Zhang G, Wang J, Guo Y, Liang C, Cen S, Wang Y. Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase. Eur J Med Chem. 2020 Jan 15;186:111900. Zhu M, Ma L, Zhou H, Dong B, Wang Y, Wang Z, Zhou J, Zhang G, Wang J, Liang C, Cen S, Wang Y. Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants. Eur J Med Chem. 2020 Jan 1;185:111866. Lv K, Wu S, Li W, Geng Y, Wu M, Zhou J, Li Y, Gao Q, Liu M. Design, synthesis and anti-HBV activity of NVR3-778 derivatives. Bioorg Chem. 2020 Jan;94:103363. Cui X, Zhang R, Cen S, Zhou J(通讯作者). STING modulators: Predictive significance in drug discovery. Eur J Med Chem. 2019 Nov 15;182:111591. doi: 10.1016/j.ejmech.2019.111591. Wang J, Zhang Y, Li Q, Zhao J, Yi D, Ding J, Zhao F, Hu S, Zhou J, Deng T, Li X, Guo F, Liang C, Cen S. Influenza Virus Exploits an Interferon-Independent lncRNA to Preserve Viral RNA Synthesis through Stabilizing Viral RNA Polymerase PB1.Cell Rep. 2019 Jun 11;27(11):3295-3304.e4. doi: 10.1016/j.celrep.2019.05.036Meng Wu, Yongli Xie, Xiangling Cui, Chenchao Huang, Rongyu Zhang,Yang He, Xiaoyu Li, Mingliang Liu, Shan Cen, Jinming Zhou (通讯作者) Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist. European Journal of Medicinal Chemistry 2019, 166 2019 232-242. Jiwei Ding, Ling Ma, Jianyuan Zhao, Yongli Xie, Jinming Zhou, Xiaoyu Li and Shan Cen An integrative genomic analysis of transcriptional profiles identifies characteristic genes and patterns in HIV-infected long-term non-progressors and elite controllers. Journal of Translational Medicine 2019 17:35 Liu Yangguang, Wu Meng, Wang Tianqi, Xie Yongli, Cui Xiangling, He Liujun, He Yang, Li Xiaoyu, Liu Mingliang, Hu Laixing, Cen Shan, Zhou Jinming (通讯作者) Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding SiteFrontiers in Pharmacology 2018(9), 1419-1429. Ding J, Zhao J, Zhou J, Li X, Wu Y, Ge M, Cen S. Association of gene polymorphism of SDF1(CXCR12) with susceptibility to HIV-1 infection and AIDS disease progression: A meta-analysis. PLoS One. 2018 13(2):e0191930.Wang J, Wang Y, Zhou R, Zhao J, Zhang Y, Yi D, Li Q, Zhou J, Guo F, Liang C, Li X, Cen S. Host Long Noncoding RNA lncRNA-PAAN Regulates the Replication of Influenza A Virus. Viruses. 2018 10(6). pii: E330. Yi DR, An N, Liu ZL, Xu FW, Raniga K, Li QJ, Zhou R, Wang J, Zhang YX, Zhou JM, Zhang LL, An J, Qin CF, Guo F, Li XY, Liang C, Cen S. Human MxB Inhibits the Replication of Hepatitis C Virus. J Virol. 2018 93(1). pii: e01285-18.Li Quanjie , Ma Ling , Yi Dongrong , Wang Han , Wang Jing , Zhang Yongxin , Guo Ying , Li Xiaoyu , Zhou Jinining* (共同通讯), Shi Yi* , Gao George F. , and Cen Shan*. Novel cyclo-peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein, Antiviral Res. 2018, 155, 1-11.Ling Ma, Zhixin Zhang, Zhenlong Liu, Qinghua Pan, Jing Wang, Xiaoyu Li, Fei Guo, Chen Liang, Laixing Hu, Jinming Zhou* (共同通讯),Shan Cen*. Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation Scientific Reports. 2018, 8, 8067.Congjie Zhai , Ling Ma et al Jinming Zhou* (共同通讯), Shan Cen* Identification and characterization of loop7 motif and its role in regulating biological function of human APOBEC3G through molecular modeling and biological assay Acta Pharmaceutica Sinica B 2017;7(5):571–582 (SCI)Yong-Xin Zhang, Yu-Ming Huang, Quan-Jie Li, Xiao-Yu Li, Yong-Dong Zhou, Fei Guo, Jin-Ming Zhou*(共同通讯), Shan Cen* A highly conserved amino acid in VP1 regulates maturation of enterovirus 71 PLOS Pathogens h 2017 , 13 (9) :e1006625 . Chao Chen, Meng Wu, Shan Cen, Jianhui Wu and Jinming Zhou (通讯作者)MTLD, a Database of Multiple Target Ligands, the Updated Version Molecules 2017, 22(9), 1375. (SCI, IF 2.9). Xu J ,Wang JX , Zhou JM, Xu CL, Huang B, Xing Y, Wang B, Luo R, Wang YC, You XF, Lu Y , Yu LY A novel protein kinase inhibitor IMB-YH-8 with anti-tuberculosis activity Scientific Reports2017, 7(1):5093 (SCI, JCR 1区, IF 4.26). Ding J, Zhao J, Yang Z, Ma L, Mi Z, Wu Y, Guo J, Zhou J,et al Microbial Natural Product Alternariol 5-O-Methyl Ether Inhibits HIV-1 Integration by Blocking Nuclear Import of the Pre-Integration Complex. Viruses. 2017 10;9(5). pii: E105. doi: 10.3390/v9050105.Yang He, Meng Wu, Yangguang Liu, Quanjie Li, Xiaoyu Li, Laixing Hu,* Shan Cen,* and Jinming Zhou# (通讯作者) Identification of Triptophenolide from Tripterygium wilfordii as a Panantagonist of Androgen Receptor ACS Med. Chem. Lett. 2016 ACS Med Chem Lett. 2016 Sep 28;7(12):1024-1027.Zhou Jinming*, Li Quanjie, Wu Meng, Chen Chao, Cen Shan. Progress in the rational design for polypharmacology drug.Curr Pharm Des. 2016;22(21):3182-9. .何阳,刘阳光,丁寄葳,李晓宇,岑山,周金明# (通讯作者).以雄激素受体为靶标的抗前列腺癌药物筛选模型的建立和应用药学学报2016, 51(2): 287-293.Li Q, Fan S, Li X, Jin Y, He W, Zhou J (共同通讯), Cen S, Yang Z. Insights into the Phosphoryl Transfer Mechanism of Human Ubiquitous Mitochondrial Creatine Kinase. Sci Rep. 2016 Dec 2; 6:38088. Q Zhang, Z Mi, Y Huang, L Ma, J Ding, J Wang, Y Zhang, J Zhou, F Guo, X Li*, S Cen*. 2-thio-6-azauridine Inhibits Vpu Mediated BST-2 Degradation. Retrovirology. 2016;13(1):13.Zheng YB, Gong JH, Liu XJ, Wu SY, Li Y, Xu XD, Shang BY, Zhou JM, Zhu ZL, Si SY, Zhen YS. A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity Sci Rep. 2016; 6:31472. Chao Chen, Yang He, Jianhui Wu, Jinming Zhou# (通讯作者) Creation of a free, Internet-accessible database: the Multiple Target Ligand Database. Journal of Cheminformatics 2015, 7:14.Xiaohong Tian, Yang He, Jinming Zhou# (通讯作者) Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance. Frontiers in Pharmacology2015, Vol6, 57.何阳,刘阳光,岑山,周金明# (通讯作者).前列腺癌耐药机制的研究进展.药学学报. 2015, 50 (7): 797 −801.Lexing Xu, Xin Wang, Hongwei He, Jinming Zhou, Xiaoyu Li, Hongtao Ma,Zelin Li,Yi Zeng,Rongguang Shao,*Shan Cen,*,Yucheng Wang*,structure-Based Design of Novel Chemical Modification of the 3′-Overhang for Optimization of Short Interfering RNA Performance Biochemistry 2015, 54, 1268-1277. Li, Fengwen Xu, Siqi Hu, Jinming Zhou, Shan Mei, Xiaoxiao Zhao, Shan Cen, Qi Jin, Chen Liang, Fei Guo. Characterization of the interactions between SIVrcm Vpx and red-capped mangabey . Biochem J. 2015, 468(2), 303-13. Zeyun Mi, Xin Wang, Yang He, Xiaoyu Li, Jiwei Ding, Hongyun Liu, Jinming Zhou# (共同通讯作者), Shan Cen A novel peptide to disrupt the interaction of BST-2 and Vpu Biopolymers (Pept Sci) 2014, 102, 280–287. Xin Wang, Xiaoyu Li, Jing Ma, Li Zhang, Ling Ma, Zeyun Mi, Jinming Zhou, Fei Guo, Lawrence Kleimanb, Shan Cen. Human APOBEC3F incorporation into human immunodeficiency virustype 1 particles. Virus Research 2014, Vol191, P30–38.Weiguo Liu, Jinming Zhou, Guoyan Geng, Rongtuan Lin, Jian Hui Wu Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB Investigational New Drugs 2014, Vol 32(2), 227-234.Zhixin Zhang, Congjie Zhai, Zeyun Mi, Jiwei Ding, Yongxin Zhang, Xing Shi, Xiaoyu Li, Liyan Yu, Zhuorong Li, Jiandong Jiang, Jinming Zhou# (共同通讯作者), Shan Cen* Molecular modeling of Human A3G to predict the binding modes of the inhibitor compounds IMB26 and IMB35. Acta Pharmaceutica Sinica B, 2013, 3, 239-244.Xiaojing Pang, Siqi Hu, Jian Li1, Fengwen Xu, Shan Mei1, Jinming Zhou, Shan Cen, Qi Jin* and Fei Guo* Identification of novel key amino acids at the interface of the transmembrane domains of human BST-2 and HIV-1 Vpu Retrovirology 2013, 10, 84. Zhenlong Liu, Qinghua Pan, Shilei Ding, Jin Qian, Fengwen Xu, Jinming Zhou, Shan Cen, Fei Guo and Chen Liang The interferon-inducible MxB protein inhibits HIV-1 infection The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host & Microbe, 2013, 14(4):398-410. Zhang YX, Wei T, Li XY, Yin X, Li YH, Ding JW, Zhou JM, Zhang GZ, Jin Q, Cen S: Construction and characterization of an infectious cDNA clone of enterovirus type 71 subgenotype C4. Virus Genes 2013, 47(2):235-243.Ma J, Li X, Xu J, Zhang Q, Liu Z, Jia P, Zhou J, Guo F, You X, Yu L et al: The roles of APOBEC3G complexes in the incorporation of APOBEC3G into HIV-1. PloS one 2013, 8(10):e74892.Jinming Zhou# (共同通讯作者), Zhixin Zhang, Zeyun Mi, Xin Wang, Quan Zhang, Xiaoyu Li, Chen Liang, and Shan Cen#. Characterization of the interface of BST-2/Vpu protein complex via computational chemistry. Biochemistry, 2012, 51, 1288-1296. Yang ZHANG*, Jinming ZHOU* (共同第一作者), Ming CHANG*, Liping BAI, Junjie SHAN, Chen YAO, Rong JIANG, Lian-hong GUO, Ren ZHANG, Jian-bo WU, Yuan LI. Characterization and functional evidence for Ste27 of Streptomyces sp. 139 as a novel spermine/spermidine acetyltransferase. Biochemical Journal. 2012, 443(3), 727-34.Weiguo Liu, Jinming Zhou, Guoyan Geng,Qingwen Shi,Francoise Sauriol, Jian Hui Wu.Antiandrogenic, maspin induction and anti-prostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A. Journal of Medicinal Chemistry, 2012, 55(2), 971-975.Quan Zhang, Zhenlong Liu, Xiaoyu Li, Zeyun Mi, Pingping Jia, Jinming Zhou, Xuefu You, Liyan Yu, Fei Guo, Jing Ma, Chen Liang, Qi Jin, Jiandong Jiang, Shan Cen. High-throughput assay to identify inhibitors of Vpu-mediated down-regulation of cell surface BST-2. Antiviral Research, 2011, 91(3), 321-329. Xiaoyu Li, Jing Ma, Quan Zhang, Jinming Zhou, Liyan Yu, Fei Guo, Qi Jin, Lixun Zhao, Yi Zeng, Shan Cen. Functional analysis of two cytidine deaminase domains in APOBEC3G. Virology, 2011, 414 (2), 130-6. Jin-Ming Zhou, Guo-Yan Geng, Gerald Batist,Jian-Hui Wu*. Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. Investigational New Drugs, 2010, 28(3), 291-298. Jin-Ming Zhou, Bing Liu, Jian-Hui Wu*. Study of the impact of the T877A mutation on ligand- induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens. Proteins, 2010, 78, 623-637. Jin-Ming Zhou, Guoyan Geng, Qingwen Shi, Francoise Sauriol, Jian Hui Wu*. Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming anti-androgen resistance. Journal of Medicinal Chemistry, 2009, 52 (17), 5546-5550. (SCI, JCR 1区, IF 5.614) Jin-Ming Zhou, Guo-Yan Geng, Gerald Batist, Jian-Hui Wu*. Syntheses and potential anti-prostate cancer activities of ionone-based chalcones. Bioorganic & Medicinal Chemistry Letters, 2009, 19, 1183–1186.Jin-Ming Zhou, Jun-Hong Zhou, Hua-Bei Zhang, Xi-Cheng Dong and Min-Bo Chen*. The different position fluoro-substitution effect of fluoro D-glucoses comparing to D-glucose: Random conformational search and Quantum chemical calculation. Carbohydrate Research, 2006, 341, 2224-2232. Jin-Ming Zhou, Jun-Hong Zhou, Yi Meng and Min-Bo Chen*. Molecular dynamics simulation of iminosugar inhibitor-glycosidase complex: Insight into the binding mechanism of 1-deoxynojirimycin and isofagomine towardsβ-glucosidase. Journal of Chemical Theory and Computation, 2006, 2, 157-165. 专利[1] Jian Hui Wu*, Weiguo Liu, Jinming Zhou, Guoyan Geng. Novel Tanshinone derivatives as anticancer agents, U.S. Provisional B&P File No. (in progress).[2] Jian-Hui Wu*, Gerald Batist, Jin-Ming Zhou, Guo-Yan Geng. Hybrid molecules of dietary agents as anticancer agents, U.S. Provisional B&P File No. 14657-32. (已授权)[3] 周金明,何阳,李晓宇,岑山等雷酚内酯作为雄激素受体拮抗剂的应用申请号: 201510954671.6 (已授权)[4] 岑山, 张全, 李晓宇, 魏晓露, 刘振龙, 贾平平, 周金明.抑制Vpu下调BST2的抗HIV药物筛选方法, 申请号: 201010123002.1. [5] 贾平平, 张义, 李晓宇, 周金明, 殷霄, 岑山*. 一种抗结核药物高通量筛选模型的构建方法. 申请号: 201110166552.6.[6]周金明马铃张志鑫李晓宇岑山 IMB-301制备抗病毒药物中的应用申请号: 2016112674610 (已授权)[7]周金明,刘阳光,李晓宇,岑山等IMB-A6作为雄激素受体拮抗剂的应用申请号: 2017101325856 (已授权) [8] 周金明,吴萌,张荣玉,黄晨超,李晓宇,岑山ZJU-IMB-Z19化合物在治疗前列腺癌中的应用申请号:201811431643.6. (已授权)[9] 周金明,吴萌,张荣玉,黄晨超,李晓宇,岑山ZNU-IMB-Z15化合物在治疗前列腺癌中的应用申请号:202010068276.9 (已授权)[10]周金明,崔香玲,周睿,李晓宇,岑山 ZP10在制备以寨卡病毒蛋白酶为靶点的抗寨卡病毒药物中的应用;201911101408.7.(已授权)[11] 周金明,谢永丽,崔香玲,丁寄葳,李晓宇,岑山; 201910233853.2.(已授权)[12] 岑山;吴萌;周金明;李晓宇; IMB-ZNU-G8在治疗雄激素受体活性相关疾病中的应用 申请号:CN202010379303.4.[13] 周金明,张荣玉,黄坊娇,张若影.基于异恶唑取代苯甲酰胺类衍生物及抗前列腺癌药物应用. 专利号:202111060327.4 (授权:2023年08月25日)。[14]周金明,许倩,黄晨超,张荣玉.一种吡唑酰胺类衍生物及合成方法和应用. 专利号:202111060328.9 申请日期:2021 年09 月10 日。[15] 周金明,韩小利,李晨帆,张荣玉. 雄激素受体和糖皮激素受体双靶抑制剂及其应用. 专利号:2023111513679,申请日期:2023 年 09 月 07 日。16] 周金明,包旗旗,章建涛,温佳佳 一类作用于 APOBEC3G 化合物及其在制备抗病毒药物中的应用.专利号:202311151360.7,申请日期:2023 年 09 月 07 日。 软件著作权. 多靶点配体检索系统v2.0, 登记号:2021RS1476264,发证日期:2021年10月9日。

Research Focus
  • .多靶点药物设计方法开发,以及在药物研发方面的应用。
  • .肿瘤免疫小分子药物的开发,尤其是针对免疫检测点(Immune checkpoint)蛋白PD-1/PD-L1以及固有免疫关键蛋白STING等.
  • .针对癌症及病毒的关键靶点, Molecular glue, PROTACs等蛋白降解分子设计和合成
workexperience

No content

Education Background

No content

Social Affiliations

No content

Research Group

No content

+

Doctorate

周金明
MOBILE Version